News

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...
Denmark's Novo Nordisk said on Tuesday it had submitted a new, higher dose of its obesity treatment Wegovy to the European ...
Novo Nordisk is in the lead, but not alone. Obesity doctors say they are gearing up for demand, predicted to be high. Some ...
Italian authorities on Monday appointed a special commissioner to help Danish drugmaker Novo Nordisk speedily deliver its ...
Novo Nordisk A/S (NYSE:NVO) is one of the 11 Best Foreign Stocks to Buy According to Hedge Funds. On June 18, TD Cowen ...
Novo Nordisk submits a higher 7.2 mg dose of Wegovy for EMA approval, backed by trials showing 21% weight loss in obesity and ...
SEOUL, SOUTH KOREA - Media OutReach Newswire - 9 July 2025 - Health2Sync, Asia's leading digital chronic disease management ...
Stocks that pay dividends tend to outperform ones that don't. Consensus price targets for Novo Nordisk suggest the stock can ...
Discover why Novo Nordisk's current sell-off offers a strong buy opportunity. Backed by solid fundamentals, growth prospects, ...
Analysts said the deal with Novo was likely giving Hims “‘credibility’ or increased consumer traffic,” adding that the ...
Investing.com -- Novo Nordisk (NYSE: NVO) stock rose 1% after the company announced it has submitted an application to the ...
DexCom has significant room to grow in its core market, despite disappointing results last year. One of Warren Buffett's ...